About this trial
Oral immunotherapy(OIT) is effective in desensitized food allergy. OIT protocols are not standardized, and a wide heterogeneity exists in the literature . So the purpose of our study is to compare short term unresponsiveness rate between once daily dose and four times/week dose during one year maintenance phase of wheat OIT
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 5-18 years old
Children aged 5-18 years with history of IgE mediated wheat allergy and positive OFC test
Reach target maintenance dose of wheat OIT and ongoing to maintenance phase of wheat OIT
Disqualifiers
Patient with low dose OIT protocol
Patients with uncontrolled atopic dermatitis, uncontrolled asthma, or any chronic disease;
Patients who had been treated with some other immunotherapy (eg, SLIT, another OIT) or biologic therapy (eg, Omalizumab)
Patients with a developmental problem or mental disorder
Trial design
Parallel
Treatments tested in this trial
Wheat (Four times per week)
Other interventionCase wheat allergy that on four times/week dose during one year maintenance phase of wheat OIT
Treatment groups
Trial outcomes
Primary outcomes
Short term unresponsiveness rate
Short term unresponsiveness rate between once daily dose and four times/week dose .during maintenance phase of wheat OIT. Short term unresponsiveness means patients who pass the oral food challenge test after stopping oral immunotherapy for a short period
Secondary outcomes
Specific IgE to wheat
Specific IgE to wheat
Specific IgG4 to wheat
Specific IgG4 to wheat
Changing in Body weight
Changing in Body weight in kilograms
Compliance
Compliance of wheat ingestion (group A: every day, groupB: 4 days/weeks). Compliance can be calculated by dividing the number of days on which wheat is actually ingested by the total number of days prescribed for wheat consumption.
Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.